Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5123
Abstract: Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy… read more here.
Keywords: hepatocellular carcinoma; safety lenvatinib; lenvatinib; recurrent hepatocellular ... See more keywords
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00983-7
Abstract: In the REFLECT trial, lenvatinib showed superior clinical benefits to sorafenib in terms of progression-free survival and was non-inferior for overall survival in the treatment of advanced hepatocellular carcinoma (HCC). We assessed the cost-effectiveness of… read more here.
Keywords: lenvatinib; treatment; cost effectiveness; cost ... See more keywords
Investigation on the binding behavior between BSA and lenvatinib with the help of various spectroscopic and in silico methods
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Molecular Structure"
DOI: 10.1016/j.molstruc.2019.127521
Abstract: Abstract Lenvatinib was a multi-tyrosine kinase inhibitor (TKI) used for treating advanced renal cell carcinoma and differentiated thyroid cancer. Multiple fluorescence spectroscopy including SSF, SF, 3DF, UV, FTIR, and molecular modeling were utilized for better… read more here.
Keywords: lenvatinib; bsa; behavior bsa; binding behavior ... See more keywords
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.104920
Abstract: Anaplastic thyroid cancer (ATC) is a rare neoplasia with a poor prognosis. Proliferation and apoptosis assays were performed on ATC cell lines (8305C, 8505C) exposed to vinorelbine, lenvatinib, as well as to concomitant combinations. ABCB1,… read more here.
Keywords: lenvatinib; combination; anaplastic thyroid; thyroid cancer ... See more keywords
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Sign Up to like & getrecommendations! Published in 2018 at "The Lancet"
DOI: 10.1016/s0140-6736(18)30207-1
Abstract: BACKGROUND In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients… read more here.
Keywords: hepatocellular carcinoma; lenvatinib; trial; carcinoma ... See more keywords
Combination therapy for HCC: from CRISPR screening to the design of clinical therapies
Sign Up to like & getrecommendations! Published in 2021 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00775-1
Abstract: CRISPR screening has been broadly used to discover new therapy targets, but these finding’ successful clinical transition is still limited. In a recent study published in Nature, Jin et al. adopted CRISPR screening to dissect… read more here.
Keywords: combination; lenvatinib; hcc; therapy ... See more keywords
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Expert review of anticancer therapy"
DOI: 10.1080/14737140.2022.2039123
Abstract: ABSTRACT Introduction Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. The recommended starting doses for lenvatinib differ across cancer types and indications based on… read more here.
Keywords: monotherapy combination; safety; lenvatinib; efficacy ... See more keywords
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1530212
Abstract: ABSTRACT Introduction: Lenvatinib, a multi-kinase inhibitor, has demonstrated improved outcomes for patients with hepatocellular carcinoma (HCC) in clinical trials. The phase 3 REFLECT trial confirmed the noninferiority of lenvatinib to sorafenib for overall survival of… read more here.
Keywords: hepatocellular carcinoma; lenvatinib; hcc; treatment ... See more keywords
Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer science"
DOI: 10.1111/cas.15095
Abstract: Anaplastic thyroid cancer (ATC) is an extremely aggressive tumor associated with poor prognosis due to a lack of efficient therapies. In Japan, lenvatinib is the only drug approved for patients with ATC; however, its efficacy… read more here.
Keywords: lenvatinib; irak1 inhibitor; inhibitor; anaplastic thyroid ... See more keywords
Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 + CD8 + T cells in HCC via blocking VEGFR2
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15719
Abstract: Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1+ CD8+ T cells in HCC microenvironment have not… read more here.
Keywords: lenvatinib; cells hcc; cd8 cells; treatment ... See more keywords
Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology Research"
DOI: 10.1111/hepr.13294
Abstract: Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long‐term antitumor activity,… read more here.
Keywords: hepatocellular carcinoma; lenvatinib; term antitumor; long term ... See more keywords